Announcement on Subsidiary Injectable Leuprolide Acetate (II) Obtaining Drug Registration Certificate

Stock Code: 000661 Stock Abbreviation: Changchun High-Tech Announcement No.: 2026-053 Changchun High-Tech Industries (Group) Co., Ltd. Announcement on Subsidiary Injectable Leuprolide Acetate (II) Obtaining Drug Registration Certificate The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions. Recently, Changchun High-Tech Industries (Group) Co., Ltd. (hereinafter referred to as the "Company") received a Drug Registration Certificate issued by the National Medical Products Administration for its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"). The domestic production drug registration and marketing license application for Jinsai Pharmaceutical's injectable leuprolide acetate (II) has been approved. The relevant approval conclusion is hereby announced as follows: I. Basic Information of the Drug Product Name: Injectable Leuprolide Acetate (II) Registration Category: Chemical Drug Class 2.2 Approved Specification: 3.75mg (calculated a